Listed as one of Top 5 Marijuana Stocks to Watch i
Post# of 82
Posted On: 02/11/2015 12:19:55 PM
Listed as one of Top 5 Marijuana Stocks to Watch in 2015 (marijuanastocks.com)
Feb 11, 2015
http://marijuanastocks.com/top-5-marijuana-st...atch-2015/
Stevia Corporation (STEV)
Also looking to benefit from patent filing is Stevia Corporation (STEV). The company, which recently switched focus from sugar alternatives to cannabis, has released a series of press relating to the filing of provisional patents for its CBD based pain medication, which is actually a mix of cannabidiol and ibuprofen. In a January 29th release, George Blankenbaker, President of Stevia Corp stated, “We believe that there will be significant advantages of using these four very effective drugs in combination with cannabidiol as opposed to using these drugs alone. Acetaminophen, Ibuprofen, Naproxen and Aspirin generate billions of dollars in sales each year. Our four provisional patent applications include 63 claims in total and we look forward to filing the utility patents over the next 12 months. We strongly believe that our intellectual property strategy, if successfully implemented, will provide us a competitive advantage over other healthcare companies using cannabinoids for human healthcare.”
The obvious advantages should these patents be approved are similar to that of GW: offering a larger advantage to being the “first to market” organization and to further limit other companies from throwing a hat into the ring. Risks abound however especially with the current state of Stevia’s market. The most recently filings show that that company obtains most of its money from farming activities. Even though the quarterly shows a cost of revenue of nearly $2m, its additional paid in capital amounts to $16.3million. Should this patent process not pan out, there is still an entirely established and revenue producing side of Stevia that won’t depend on cannabis. On a market side, Stevia’s stock has begun to recover since hitting lows earlier in January of $0.064. As of this past week, STEV has seen a rebound of roughly 30% since releasing announcements on this latest patent filing.
Feb 11, 2015
http://marijuanastocks.com/top-5-marijuana-st...atch-2015/
Stevia Corporation (STEV)
Also looking to benefit from patent filing is Stevia Corporation (STEV). The company, which recently switched focus from sugar alternatives to cannabis, has released a series of press relating to the filing of provisional patents for its CBD based pain medication, which is actually a mix of cannabidiol and ibuprofen. In a January 29th release, George Blankenbaker, President of Stevia Corp stated, “We believe that there will be significant advantages of using these four very effective drugs in combination with cannabidiol as opposed to using these drugs alone. Acetaminophen, Ibuprofen, Naproxen and Aspirin generate billions of dollars in sales each year. Our four provisional patent applications include 63 claims in total and we look forward to filing the utility patents over the next 12 months. We strongly believe that our intellectual property strategy, if successfully implemented, will provide us a competitive advantage over other healthcare companies using cannabinoids for human healthcare.”
The obvious advantages should these patents be approved are similar to that of GW: offering a larger advantage to being the “first to market” organization and to further limit other companies from throwing a hat into the ring. Risks abound however especially with the current state of Stevia’s market. The most recently filings show that that company obtains most of its money from farming activities. Even though the quarterly shows a cost of revenue of nearly $2m, its additional paid in capital amounts to $16.3million. Should this patent process not pan out, there is still an entirely established and revenue producing side of Stevia that won’t depend on cannabis. On a market side, Stevia’s stock has begun to recover since hitting lows earlier in January of $0.064. As of this past week, STEV has seen a rebound of roughly 30% since releasing announcements on this latest patent filing.
(0)
(0)